Providers utilize business intelligence to monitor referral patterns and collaborate with clinicians who order their services. Such analytics tools have also been deployed in the specialty to improve productivity, track patient satisfaction and bolster quality.
The Pennsylvania-based drug distributor announced it would be buying OneOncology, a physician-led specialty service group in which it already owned a minority stake. The company said the acquisition will complement its "pharmaceutical-centric strategy."
Paxton says the “woke” EHR giant is intentionally making it harder for patients and families to access historical medical data, violating state law. Epic denies the allegation.
Mark Cuban's startup Cost Plus Drugs and insurer Humana are said to be working on a deal that would allow Medicare Advantage patients to buy drugs directly from manufacturers. The terms of the agreement—which Forbes reports is in its early stages—are still unknown.
The results were shown in multiple posts on X. A clinical trial to prove the safety and efficacy of Elon Musk's brain implant is ongoing, with 12 people currently using the devices.
If healthcare AI is to flourish outside of academic research settings and industry R&D departments, it will need to win over its most difficult-to-impress audience: healthcare workers in hospitals.
It stands to reason that the branch of healthcare most reliant on the use of language in clinical practice would embrace large language AI. But is U.S. mental healthcare on board with the notion?
Malissa Wood, MD, associate chief of cardiology for diversity and equity at Massachusetts General Hospital, explains the role of health equity in cardiovascular care and what her health system is doing to address it.
A new analysis reveals that insurers could put between $228 million and $2.15 billion back in taxpayers’ pockets by purchasing a series of generic oncology medications at the same prices obtained by the Mark Cuban Cost Plus Drug Company.